Drug Discovery

Roivant Sciences secures rights to develop Ligand’s glucagon receptor antagonist

Ligand Pharmaceuticals has signed a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize its LGD-6972 glucagon receptor antagonist (GRA).

Caladrius acquires license to CD34+ cell therapy program from Shire

Caladrius Biosciences has acquired an exclusive worldwide license to data from Shire’s late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.

Research reveals bacteria could be programmed to produce drugs

Research into synthetic biology from the Universities of Warwick and Surrey has revealed that bacteria could be programmed to produce drugs.

Mylan to launch two new HIV combination treatments in US

Mylan said that it will launch two new HIV treatments, Symfi Lo and Cimduo, which have been approved in February this year by the US Food and Drug Administration (FDA).

LEO Pharma sells major product portfolio to Karo Pharma for €260m

LEO Pharma has sold product portfolio of 10 products to Swedish company Karo Pharma for €260m.

AstraZeneca’s MedImmune spins out biotech to focus on autoimmune candidates

MedImmune, the global biologics research and development arm of AstraZeneca, is creating a stand-alone company for early-stage inflammation and autoimmunity biologics.

Senti Biosciences secures $53m funding to advance therapeutic design platform

Senti Biosciences has completed a $53m round of funding to support the expansion of their therapeutic design platform.

BenevolentAI buys drug discovery and development facility in Cambridge, UK

BenevolentAI has acquired an advanced drug discovery and development facility on the Babraham Research Campus in Cambridge, UK, for an undisclosed sum.

New collaborative project to develop Zika virus vaccine for pregnant women

A new collaborative project has been launched to develop a Zika virus vaccine that is suitable for use in pregnancy.